Inflammatory mediators after endovascular aortic aneurysm repair

A stable aneurysm sac after endovascular aneurysm repair as a predictor for mortality, an in-depth analysis

OBJECTIVES

The aim of this study was to compare the long-term survival in patients with a stable aneurysmal sac and those with aneurysmal sac regression after endovascular aneurysm repair (EVAR) and to identify independent risk factors for aneurysmal sac regression and mortality after EVAR.

METHODS

We reviewed all patients who underwent EVAR between 2005 and 2018 with a computed tomography angiography available at 1-year follow-up. Aneurysm sac regression was defined as a diameter decrease of more than 10%. We used a multivariable regression to identify independent risk factors for sac regression. Kaplan-Meier analysis and Cox regression were done to test differences in 5-year mortality between a stable sac and sac regression.

RESULTS

The inclusion criteria were met by 325 patients, 185 in the sac regression group and 140 in the stable sac group. Multivariable logistic regression analysis showed that treatment for a ruptured aneurysm was an independent risk factor for aneurysmal sac regression (hazard ratio [HR], 0.26; 95% confidence interval [CI], 0.07-0.96). Age (HR, 1.05; 95% CI, 1.01-1.09), ischemic heart disease (HR, 1.94; 95% CI, 1.13-3.31), neck thrombus (HR, 2.72; 95% CI, 1.07-6.95), and a type II endoleak (HR, 19.21; 95% CI, 7.32-50.40) were independent risk factors for a stable aneurysm sac diameter. Multivariable Cox regression showed a significantly increased risk of mortality for patients with a stable aneurysm sac after EVAR (odds ratio, 2.25; 95% CI, 1.36-3.72). There was no significant difference in cause of death between the two groups.

CONCLUSION

A stable aneurysm sac after EVAR is associated with increased mortality. Age, ischemic heart disease, neck thrombus, and a type II endoleak are independent risk factors for a stable sac. However, a well-founded explanation for this finding is still lacking. Future research should be focussed on aggressive treatment of type II endoleaks and inflammatory processes as potential pathophysiological mechanisms.

Biomarkers in EndoVascular Aneurysm Repair (EVAR) and Abdominal Aortic Aneurysm: Pathophysiology and Clinical Implications

Circulating biomarkers have been recently investigated among patients undergoing endovascular aortic aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA). Considering the plethora of small descriptive studies reporting potential associations between biomarkers and clinical outcomes, this review aims to summarize the current literature considering both the treated disease (post EVAR) and the untreated disease (AAA before EVAR). All studies describing outcomes of tissue biomarkers in patients undergoing EVAR and in patients with AAA were included, and references were checked for additional sources. In the EVAR scenario, circulating interleukin-6 (IL-6) is a marker of inflammatory reaction which might predict postoperative morbidity; cystatin C is a promising early marker of post-procedural acute kidney injury; plasma matrix metalloproteinase-9 (MMP-9) concentration after 3 months from EVAR might help in detecting post-procedural endoleak. This review also summarizes the current gaps in knowledge and future direction of this field of research. Among markers used in patients with AAA, galectin and granzyme appear to be promising and should be carefully investigated even in the EVAR setting. Larger prospective trials are required to establish and evaluate prognostic models with highest values with these markers.

Identification of novel diagnostic and prognostic biomarkers for abdominal aortic aneurysm

Aims

Abdominal aortic aneurysm is a life-threatening condition due to the risk of aneurysm growth and rupture. There are no approved diagnostic or prognostic biomarkers for abdominal aortic aneurysm. We aimed to identify diagnostic and prognostic biomarkers for abdominal aortic aneurysm and to investigate their relationship with abdominal aortic aneurysm diameter and growth.

Methods

In this case-control study, patients were included from an abdominal aortic aneurysm screening study on men aged ≥65 years. Of 24,589 examined men, 415 had abdominal aortic aneurysm, out of whom 134 consented to participate in the present study. One hundred and thirty-six screened men with aortic diameter <30 mm, matched for comorbidities and time of sampling were included as non-abdominal aortic aneurysm patients. Ninety-one cardiovascular specific proteins in plasma samples were measured by the Proseek Multiplex CVD III96x96panel.

Results

After Bonferroni correction, plasma levels of 21 proteins associated with proteolysis, oxidative-stress, lipid metabolism, and inflammation were significantly increased, whereas levels of paraoxonase 3, associated with high-density lipoprotein metabolism, were decreased in abdominal aortic aneurysm patients. Combination of growth/differentiation factor 15 and cystatin B had the best ability to discriminate abdominal aortic aneurysm from non-abdominal aortic aneurysm (area under the curve, 0.76; sensitivity, 80% and specificity, 52%). Myeloperoxidase showed the best prognostic value (area under the curve, 0.71; sensitivity, 80% and specificity, 59%) and higher baseline levels of myeloperoxidase were significantly associated with faster abdominal aortic aneurysm growth compared with lower levels, independent of baseline diameter.

Conclusions

We have identified multiple proteins associated with abdominal aortic aneurysm diameter and growth with a potential to become novel diagnostic and prognostic biomarkers for abdominal aortic aneurysm.